3.37
0.30%
-0.010
After Hours:
3.17
-0.20
-5.93%
Galectin Therapeutics Inc stock is currently priced at $3.37, with a 24-hour trading volume of 204.98K.
It has seen a -0.30% decreased in the last 24 hours and a +60.48% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.36 pivot point. If it approaches the $3.47 resistance level, significant changes may occur.
Galectin Therapeutics Inc Stock (GALT) Financials Data
Galectin Therapeutics Inc (GALT) Net Income 2024
GALT net income (TTM) was -$41.07 million for the quarter ending December 31, 2023, a -5.91% decrease year-over-year.
Galectin Therapeutics Inc (GALT) Cash Flow 2024
GALT recorded a free cash flow (TTM) of -$32.97 million for the quarter ending December 31, 2023, a -6.15% decrease year-over-year.
Galectin Therapeutics Inc (GALT) Earnings per Share 2024
GALT earnings per share (TTM) was -$0.74 for the quarter ending December 31, 2023, a -13.85% decline year-over-year.
Galectin Therapeutics Inc Stock (GALT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Uihlein Richard E | Director |
Sep 26 '23 |
Option Exercise |
4.49 |
2,236,204 |
10,033,020 |
10,235,495 |
ELDRED KARY | Director |
Jul 19 '23 |
Buy |
1.79 |
1,598 |
2,854 |
48,813 |
Galectin Therapeutics Inc Stock (GALT) Latest News
Wall Street Breakfast: The Week Ahead
Seeking Alpha
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
The Motley Fool
UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
GlobeNewswire Inc.
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD
GlobeNewswire Inc.
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023
GlobeNewswire Inc.
About Galectin Therapeutics Inc
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.
Cap:
|
Volume (24h):